12.58
Schlusskurs vom Vortag:
$12.81
Offen:
$12.8
24-Stunden-Volumen:
1.00M
Relative Volume:
1.26
Marktkapitalisierung:
$1.06B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-6.19%
1M Leistung:
+7.25%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
Niagen Bioscience Inc Stock (NAGE) Company Profile
Firmenname
Niagen Bioscience Inc
Sektor
Branche
Telefon
310-388-6706
Adresse
10900 WILSHIRE BLVD, LOS ANGELES
Vergleichen Sie NAGE mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
NAGE
Niagen Bioscience Inc
|
12.58 | 1.06B | 0 | 0 | 0 | 0.00 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Niagen Bioscience Inc Stock (NAGE) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-05-27 | Eingeleitet | Canaccord Genuity | Buy |
2022-08-16 | Herabstufung | Oppenheimer | Outperform → Perform |
2022-08-11 | Herabstufung | B. Riley Securities | Buy → Neutral |
2022-03-08 | Eingeleitet | ROTH Capital | Buy |
2019-10-16 | Eingeleitet | Oppenheimer | Outperform |
2019-02-14 | Eingeleitet | B. Riley FBR | Buy |
2017-11-27 | Fortgesetzt | H.C. Wainwright | Buy |
2017-09-25 | Eingeleitet | Ladenburg Thalmann | Buy |
2017-01-03 | Eingeleitet | Rodman & Renshaw | Buy |
Alle ansehen
Niagen Bioscience Inc Aktie (NAGE) Neueste Nachrichten
Niagen Bioscience (NASDAQ:NAGE) Shares Down 2.4%Should You Sell? - MarketBeat
Market Participants Recognise Niagen Bioscience, Inc.'s (NASDAQ:NAGE) Revenues Pushing Shares 29% Higher - simplywall.st
Niagen Bioscience (NASDAQ:NAGE) Lowered to "Buy" Rating by Wall Street Zen - MarketBeat
Niagen Bioscience (NASDAQ:NAGE) Price Target Raised to $16.00 - MarketBeat
Niagen Bioscience (NASDAQ:NAGE) Downgraded to Buy Rating by Wall Street Zen - Defense World
Niagen Bioscience (NASDAQ:NAGE) Sets New 12-Month High After Analyst Upgrade - MarketBeat
Niagen Bioscience to Participate in the BIO 2025 International C - GuruFocus
Niagen Bioscience to Participate in the BIO 2025 International Convention - Business Wire
Niagen Bioscience: High Conviction, High Expectations (NASDAQ:NAGE) - Seeking Alpha
Canaccord Genuity Group Issues Positive Forecast for Niagen Bioscience (NASDAQ:NAGE) Stock Price - Defense World
Niagen Bioscience (NAGE): Analyst Reaffirms Buy Rating and Incre - GuruFocus
Niagen Bioscience (NAGE) Gains Boost with Positive Clinical Resu - GuruFocus
Niagen study shows promise for Werner Syndrome treatment By Investing.com - Investing.com South Africa
Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder - Business Wire
Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highl - GuruFocus
Niagen Bioscience stock rises following positive clinical study By Investing.com - Investing.com South Africa
Niagen Bioscience stock rises following positive clinical study - Investing.com Australia
Niagen study shows promise for Werner Syndrome treatment - Investing.com
Niagen Bioscience (NASDAQ:NAGE) Shares Gap Up After Analyst Upgrade - MarketBeat
Niagen Bioscience (NASDAQ:NAGE) Given New $23.00 Price Target at Roth Capital - MarketBeat
Niagen Bioscience (NASDAQ:NAGE) Stock Rating Lowered by Wall Street Zen - Defense World
Niagen Bioscience (NASDAQ:NAGE) Shares Gap Up on Analyst Upgrade - Defense World
Niagen Bioscience (NASDAQ:NAGE) Shares Gap Up Following Analyst Upgrade - Defense World
Roth Capital Reiterates “Buy” Rating for Niagen Bioscience (NASDAQ:NAGE) - Defense World
Niagen Bioscience (NASDAQ:NAGE) Reaches New 12-Month HighWhat's Next? - MarketBeat
Niagen Bioscience (NAGE) Target Price Raised to $23 by Roth Capi - GuruFocus
Niagen Bioscience (NAGE) Receives Price Target Boost from Roth Capital | NAGE Stock News - GuruFocus
What 4 Analyst Ratings Have To Say About Niagen Bioscience - Nasdaq
Niagen Bioscience (NAGE) Target Price Raised to $23 by Roth Capital | NAGE Stock News - GuruFocus
Niagen Bioscience (NASDAQ:NAGE) Trading 8.2% HigherShould You Buy? - MarketBeat
Niagen Bioscience Inc (NASDAQ:NAGE) Q1 2025 Earnings Call Transcript - MSN
Niagen Bioscience to Present at Oppenheimer's 25th Annual Consum - GuruFocus
Niagen Bioscience to Present at Oppenheimer's 25th Annual Consumer Growth and E-Commerce Conference | NAGE Stock News - GuruFocus
Niagen Bioscience to Present at Oppenheimer’s 25th Annual Consumer Growth and E-Commerce Conference - Business Wire
Niagen Bioscience (NASDAQ:NAGE) Reaches New 1-Year HighHere's What Happened - MarketBeat
Niagen Bioscience (NASDAQ:NAGE) Now Covered by Canaccord Genuity Group - MarketBeat
Niagen Bioscience (NASDAQ:NAGE) Coverage Initiated by Analysts at Canaccord Genuity Group - Defense World
Canaccord Genuity Initiates Coverage of Niagen Bioscience (NAGE) with Buy Recommendation - Nasdaq
Canaccord Genuity Initiates Niagen Bioscience at Buy With $13 Price Target - marketscreener.com
Canaccord starts Niagen Bioscience at Buy on ‘unique opportunity’ - TipRanks
Niagen Bioscience (NAGE) Receives Positive Outlook with $13 Pric - GuruFocus
Finanzdaten der Niagen Bioscience Inc-Aktie (NAGE)
Es liegen keine Finanzdaten für Niagen Bioscience Inc (NAGE) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Niagen Bioscience Inc-Aktie (NAGE) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Lopez Carlos Luis | SVP, General Counsel |
Mar 07 '25 |
Buy |
7.86 |
273 |
2,146 |
2,251 |
Jaksch Frank L Jr | Director |
Dec 13 '24 |
Option Exercise |
3.66 |
50,001 |
183,004 |
281,340 |
Jaksch Frank L Jr | Director |
Dec 13 '24 |
Sale |
6.19 |
37,161 |
229,956 |
244,179 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):